Aida Muhic

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9

Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience

Otto Mølby Henriksen, Vibeke A. Larsen, Aida Muhic et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 69 citations

Engineering, Pet-mri, Brain Tumour Metabolism +16

Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma

Michael Lundemann, Per Munck af Rosenschöld, Aida Muhic et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 69 citations

Engineering, Pet-mri, Multi-parametric Pet +16

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme

Aida Muhic, Hans Skovgaard Poulsen, Morten Mau‐Sørensen et al. · Journal of Neuro-Oncology · 2012 · 68 citations

Neuro-oncology, Medicine, Recurrent Glioblastoma Multiforme +8

Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine

Norbert Galldiks, Veronika Dunkl, Garry Ceccon et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 57 citations

Neuro-oncology, Glioma, Medicine +13